Kirwan et al. also reported a well-designed prospective study on the markers of hemostasis (thrombin-antithrombin (TAT), fibrinogen, D-dimer, and platelet count) and functional clotting assays (prothrombin time (PT) and aPTT and procoagulants tissue factor (TF), cancer procoagulant (CP), and plasma vascular endothelial growth factor (pVEGF)), which were measured before chemotherapy and at 24 h, 4 days, 8 days, and 3 months after chemotherapy in patients with breast cancer. The gene discussed is F3; the disease is breast cancer.